Scientific publications

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Garcia-Pavia P, aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T.

Two randomized Phase 3 studies of aducanumab in early Alzheimer's disease

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A.

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells

Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, Suhr OB, Saraiva MJ, Hock C, Nitsch RM, Grimm J.

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck PK, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky RB, Grimm J, Weinreb PH.

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Garcia-Pavia P, aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T.

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussière T, Hamann S, Cameron TO, Weinreb PH

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, Vieira FG, Kulic L, Späni C, Stehle T, Perrin S, Weber M, Hock C, Nitsch RM, Grimm J.

Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

Nobuhara CK, DeVos SL, Commins C, Wegmann S, Moore BD, Roe AD, Costantino I, Frosch MP, Pitstick R, Carlson GA, Hock C, Nitsch RM, Montrasio F, Grimm J, Cheung AE, Dunah AW, Wittmann M, Bussiere T, Weinreb PH, Hyman BT, Takeda S.

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, Bacskai BJ.

Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy

Merlini M, Wanner D, Nitsch RM.

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A

Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study

Welt T, Kulic L, Hoey SE, McAfoose J, Späni C, Chadha AS, Fisher A, Nitsch RM.

Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy

Jelcic I, Combaluzier B, Jelcic I, Faigle W, Senn L, Reinhart BJ, Ströh L, Nitsch RM, Stehle T, Sospedra M, Grimm J, Martin R.

Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology

Serrano-Pozo A1, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.

Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice

Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM.

Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology

Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, Geyer BC, Ravid R, Mor TS, Nitsch RM, Soreq H.

M1 receptors play a central role in modulating AD-like pathology in transgenic mice

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM.

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM.

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM.

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease

Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM.

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

Götz J, Chen F, van Dorpe J, Nitsch RM.

The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease

Nitsch RM1, Deng M, Tennis M, Schoenfeld D, Growdon JH

Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment.

Hock C, Golombowski S, Naser W, Müller-Spahn F.

Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype

Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT,

Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices

Nitsch RM1, Farber SA, Growdon JH, Wurtman RJ

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.